USA flag logo/image

An Official Website of the United States Government

Oral Delivery of Thrombostatin

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
65772
Program Year/Program:
2003 / SBIR
Agency Tracking Number:
HL075229
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
TSRL, INC.
540 AVIS DR, STE A ANN ARBOR, MI -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2003
Title: Oral Delivery of Thrombostatin
Agency: HHS
Contract: 1R43HL075229-01
Award Amount: $205,333.00
 

Abstract:

DESCRIPTION (provided by applicant): The hypothesis of this proposal is that the di- or tri-peptide transporter in the gastrointestinal tract can be used as a means to absorb orally delivered peptides as therapeutics in vivo. Recent information indicates that the bradykinin breakdown product of angiotensin converting enzyme, the pentapeptide Arg-Pro-Pro-Gly-Phe (RPPGF), which we have named "Thrombostatin TM' has the ability to interact with the extracellular fragment of protease activated receptor 1 (PAR1), the thrombin receptor, to prevent thrombin cleavage and activation. Investigations presently will determine if these anti-thrombin peptides can be orally adsorbed to be active thrombin inhibitors in vivo. The specific aims of this proposal are as follows: Specific aim #1: Evaluate the chemical and enzymatic stability of Thrombostatin TM derivatives in intestinal fluids to create more stable, orally absorbable compounds with increased inhibitory activity. Specific aim #2: Investigations will determine in rats if there is oral absorption of these thrombin inhibitory peptides to act as inhibitors of thrombin activation of platelets. The purpose of these investigations is two-fold. First, investigations will be performed to determine the most stable forms of the RPPGF derivatives that can be absorbed from the gastrointestinal tract. Second, studies will be performed to determine if oral absorption of RPPGF derivatives inhibit thrombin activation of platelets. These investigations aim to develop an oral form of a platelet-selective thrombin inhibitor. Such an agent will be useful in the management of acute coronary syndromes and other disorders of thrombosis.

Principal Investigator:

John M. Hilfinger
7346634233
jhilfinger@tsrlinc.com

Business Contact:

John Hilfinger
7346634233
JHILFINGER@TSRLINC.COM
Small Business Information at Submission:

TSRL, INC.
TSRL, INC. 540 AVIS DR, STE A ANN ARBOR, MI 48108

EIN/Tax ID: 382651827
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No